All News
News Center
Hot News
The festive atmosphere of the Spring Festival has not yet dissipated, and Lujiazhen enterprises have switched from the "Spring Festival mode" to the "production mode". Promote production, ensure supply and catch up with orders. Full of riveting power, right to sprint the Year of the Rabbit.
2023 / 08 / 31
Dequan Pharmaceutical (Jiangsu) Co., LTD. Hazardous waste production unit information publicity
Dequan Pharmaceutical (Jiangsu) Co., LTD. Hazardous waste production unit information publicity
More
2023 / 08 / 31
The results of the selection of the eighth batch of state-organized centralized procurement of drugs were fully implemented
The results of the selection of the eighth batch of state-organized centralized procurement of drugs were fully implemented
More
2022 / 12 / 17
A COVID-19 pharmaceutical manufacturer in Kunshan makes every effort to guarantee supply
Recently, the first version of the drug catalog for people infected with COVID-19 was released, in which diclofenac sodium enteric coated sustained-release capsules were included. In order to meet the increasing market demand in the near future, Dequan Pharmaceutical (Jiangsu) Co., Ltd., located in Lujia Town, is busy in its production and packaging workshops. It tries its best to adjust the production line, increase the production capacity, and increase the horsepower to produce diclofenac sodium enteric-coated capsules.
More
2018 / 07 / 26
Statement Letter on Yongxin Valsartan Preparation Not Affected by Recall Event
Dequan Pharmaceuticals (Jiangsu) Co., Ltd. hereby declares that the drug substance of Gesartan produced by the company (specification: 80mg) is not used by Zhejiang Huahai Pharmaceutical Co., Ltd., so it is not affected by the recall event.
More
2014 / 12 / 28
The Food and Drug Administration issued the 6th issue of drug quality announcement
Recently, the State Food and Drug Administration issued the latest issue of the drug quality announcement (the sixth issue of the total), announcing the quality and quantity sampling inspection of 3200 batches of 21 varieties of drugs, including acyclovir eye drops, paclitaxel injection, cassia twig tuckahoe pills, lactobacillus dispersible tablets, and compound houttuynia tablets, as well as 45 batches of drugs that failed to meet the standard after inspection.
More
2014 / 12 / 25
Yongxin continuously sells new products to the United States through FDA inspection
Yongxin Pharmaceuticals (1716) today announced that it passed the FDA factory inspection again with zero 483 missing. After the completion of this factory inspection, the company will continue to sell products in the United States and accept the entrustment of IMPAX and the United States Pharmaceutical Factory. The new products can also be sold in the United States market. It is expected that the company's export sales performance will also have significant growth opportunities.
More
2014 / 12 / 22
How to use the medical insurance money to see a doctor should be the the final say of the people
At the end of 2014, the School of Public Administration of Zhejiang University, as a third-party institution, published a blue book, "Restructuring of Public Hospitals: Theory and Policy". The authors of this independent study are the team of Professor He Ziying, associate professor of the School of Public Administration of Zhejiang University, and Professor Yu Jianxing, executive vice president, and Professor Gu Xin, School of Public Administration of Peking University. These Daniel are experts in medical reform.
More
2014 / 12 / 18
Yongxin Pharmaceuticals has opened Hefeng 153 bus around it to connect with Huaqiao Station of Shanghai Rail Transit Line 11
Surrounding Yongxin Pharmaceuticals - Hefeng 153 bus is opened to connect with Huaqiao Station of Shanghai Rail Transit Line 11. This line is the first inter-provincial subway line in China, which greatly facilitates the traffic between Kunshan and Shanghai after its opening.
More
To Top